Literature DB >> 12209879

Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2).

Bin Zhang1, Robert G Fenton.   

Abstract

The evolutionarily conserved Ras/Raf/MEK/ERK pathway is thought to be essential for proliferation of eukaryotic cells. The human multiple myeloma (MM) cell line 8226 encodes an activated K-ras allele and proliferates without requirement for the main MM growth and survival factor IL-6. Surprisingly, the addition of the MEK1/2 inhibitors PD98059 or U0126 to 8226 cultures at doses that block virtually all ERK1/2 activity had minimal effects on the rapid proliferation of this cell line. In contrast, proliferation of the IL-6-dependent MM cell line, ANBL-6 was blocked by PD98059. Levels of activated forms of the other classical MAP kinases (JNK and p38) were very low during MM cell proliferation and, therefore, do not substitute for the mitogenic activities normally regulated by ERK kinases. These data demonstrate that proliferation of 8226 cells does not require ERK1/2 activity, and suggest that IL-6-independent growth of MM may correlate with independence from a requirement for ERK activity. Other signal transduction pathways that appear to regulate cell cycle progression in these cells were examined. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209879     DOI: 10.1002/jcp.10148

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D.

Authors:  Niels Smakman; Diana J M van den Wollenberg; Inne H M Borel Rinkes; Rob C Hoeben; Onno Kranenburg
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

Authors:  A Scuto; P Krejci; L Popplewell; J Wu; Y Wang; M Kujawski; C Kowolik; H Xin; L Chen; Y Wang; L Kretzner; H Yu; W R Wilcox; Y Yen; S Forman; R Jove
Journal:  Leukemia       Date:  2010-12-17       Impact factor: 11.528

3.  IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells.

Authors:  Yanqiang Chen; Jianzhen Liu; Pei Lv; Jiangyan Gao; Mingzheng Wang; Yongjun Wang
Journal:  Cell Adh Migr       Date:  2017-06-19       Impact factor: 3.405

Review 4.  New frontiers in the treatment of multiple myeloma.

Authors:  Janice Jin Hwang; Irene M Ghobrial; Kenneth C Anderson
Journal:  ScientificWorldJournal       Date:  2006-12-06

5.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

6.  Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells.

Authors:  Tatiana M Garcia-Bates; Steven H Bernstein; Richard P Phipps
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

7.  Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens.

Authors:  Ashraf Kakoo; Mustafa Al-Attar; Taban Rasheed
Journal:  Saudi J Biol Sci       Date:  2021-09-16       Impact factor: 4.219

8.  Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

Authors:  Patrick Frost; Yijiang Shi; Bao Hoang; Joseph Gera; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.